Australia Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012

Australia Diabetes Care Devices Investment Opportunities, Analysis and Forecasts to 2012

Summary

This report is an essential source for in-depth information and data relating to the Australia diabetes care devices market. It also offers detailed and comprehensive coverage of market revenue, volume, distribution and company share information; and latest news, financial deals and pipeline products information of each of the key sub-segments of the diabetes care devices in Australia

Scope

- The report provides diabetes care devices information broken down into detailed categories and segments in Australia.
- Total revenues, products sold, end users, and average pricing.
- Market shares of all the key competitors.
- Key pipeline products that are set to shape the market, broken down by sector.
- Information on the top medical equipment companies in the sector in the country covering business description, strategic analysis, and financial information.
- Healthcare structure, regulatory environment, approval process, pricing trends and reimbursement.
- Product and brand updates, strategy changes, R&D projects, corporate expansions and contractions and regulatory changes.
- Key mergers and acquisitions, partnerships, private equity investments and IPOs.
- Customer, hospitals and physicians data.

Reasons to buy

- Gain a strong understanding of the diabetes care devices market in Australia.
- Evaluate and compare the attractiveness of the market in the country.
- Identify growth segments and opportunities in each industry sector within the country.
- Evaluate the pipeline of key products that will change the sector, and identify threats and opportunities before the products are launched in the country.
- Analyze the competitiveness of the market in the country and identify hotspots.
- Develop strategies based on the latest product, brand, expansion and research and development news in the country.
- Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the market in the country.
- Identify and analyze the strengths and weaknesses of the industry incumbents in the country. SHOW LESS READ MORE >

1 2
1.1 List of Tables 8
1.2 List of Figures 10
2 Introduction 11
2.1 What Is This Report About? 11
3 Definitions of the Markets Covered in the Report 12
3.1 Diabetes Care Devices 12
3.2 Glucose Monitoring 12
3.2.1 Blood Glucose Meter 12
3.2.2 Blood Glucose Strips 12
3.3 Insulin Delivery 12
3.3.1 Insulin Jet Injector 12
3.3.2 Insulin Pen 12
3.3.3 Insulin Pump 12
3.3.4 Insulin Syringes 13
4 Healthcare Sector Review 14
4.1 Healthcare Expenditure 14
4.2 Healthcare Infrastructure 17
4.3 Healthcare Policy 21
4.4 Australia Healthcare Trade Statistics 22
5 Regulation System 23
5.1 Medical Equipment Approval Process 23
5.1.1 Classification 23
5.1.2 Registration and Conformity Assessment 30
5.2 Advertising 32
5.3 Labeling and Packaging 33
5.4 Post-market Surveillance 34
5.5 Registration Fee 34
6 Pricing and Reimbursement 41
7 Distribution Structure 42
8 Australia Medical Equipment Cross Market Comparison 43
9 Diabetes Care Devices In Australia 45
9.1 Diabetes Care Devices Cross Country Comparison (2000-2012) 45
9.2 Diabetes Care Devices, Australia, Overall Revenues, 2000-2012 46
9.3 Diabetes Care Devices, Australia, Category Volume, 2000-2012 50
9.4 Diabetes Care Devices, Australia, Company Share (2006-2007) 53
10 Glucose Monitoring In Australia 54
10.1 Glucose Monitoring Overall Revenue (2000-2012) 54
10.2 Glucose Monitoring Overall Volume (2000-2012) 56
10.3 Glucose Monitoring Average Price (2000-2012) 58
10.4 Glucose Monitoring Distribution Share (2006-2007) 58
10.5 Glucose Monitoring, Australia, Company Share (2006-2007) 59
11 Insulin Delivery In Australia 60
11.1 Insulin Delivery Overall Revenue (2000-2012) 60
11.2 Insulin Delivery Overall Volume (2000-2012) 62
11.3 Insulin Delivery Average Price (2000-2012) 63
11.4 Insulin Delivery Distribution Share (2006-2007) 63
11.5 Insulin Delivery, Australia, Company Share (2006-2007) 64
12 F. Hoffmann-La Roche Ltd. Company Profile 65
12.1 Company Overview 65
12.2 Value Chain Analysis 65
12.2.1 Manufacturing 65
12.2.1.1 In House Manufacturing 65
12.2.1.2 Outsourcing 66
12.2.2 Product Development 66
12.2.2.1 Regulatory Approvals 66
12.2.2.2 Clinical Trials 66
12.2.2.3 Research and Development 66
12.2.3 Sales and Marketing 67
12.2.3.1 Partnerships and Alliances 67
12.2.3.2 Licensing Agreements 67
13 Bayer HealthCare AG Company Profile 68
13.1 Company Overview 68
13.2 Value Chain Analysis 68
13.2.1 Manufacturing 69
13.2.1.1 In House Manufacturing 69
13.2.1.2 Outsourcing 69
13.2.2 Product Development 69
13.2.2.1 Regulatory Approvals 69
13.2.2.2 Clinical Trials 69
13.2.2.3 Research and Development 69
13.2.3 Sales and Marketing 70
13.2.3.1 Partnerships and Alliances 70
13.2.3.2 Licensing Agreements 70
13.3 Bayer HealthCare AG Pipeline Products 70
13.3.1 Bayer HealthCare AG Pipeline Products by Equipment Type 70
13.3.2 Bayer HealthCare AG Pipeline Products by Development Stage 71
13.3.3 Bayer HealthCare AG Pipeline Products by Therapy Area 71
13.3.4 Bayer HealthCare AG Pipeline Products by News Summary 71
14 Novo Nordisk A/S Company Profile 72
14.1 Company Overview 72
14.2 Novo Nordisk A/S Pipeline Products 72
14.2.1 Novo Nordisk A/S Pipeline Products By Equipment Type 72
14.2.2 Novo Nordisk A/S Pipeline Products by Development Stage 72
14.2.3 Novo Nordisk A/S Pipeline Products by Therapy Area 73
14.2.4 Novo Nordisk A/S Pipeline Products by Clinical Trials 73
15 LifeScan, Inc. Company Profile 74
15.1 Company Overview 74
15.2 LifeScan, Inc. Pipeline Products 74
15.2.1 LifeScan, Inc. Pipeline Products By Equipment Type 74
15.2.2 LifeScan, Inc. Pipeline Products by Development Stage 74
15.2.3 LifeScan, Inc. Pipeline Products by Therapy Area 74
15.2.4 LifeScan, Inc. Pipeline Products by Clinical Trials 75
15.2.5 LifeScan, Inc. Pipeline Products by News Summary 75
16 Abbott Laboratories Company Profile 76
16.1 Company Overview 76
16.2 Value Chain Analysis 76
16.2.1 Manufacturing 76
16.2.1.1 In House Manufacturing 76
16.2.2 Product Development 77
16.2.2.1 Regulatory Approvals 77
16.2.2.2 Research and Development 77
16.2.2.3 Clinical Trials 77
16.2.3 Sales and Marketing 78
16.2.3.1 Partnerships and Alliances 78
16.3 Abbott Laboratories Pipeline Products 78
16.3.1 Abbott Laboratories Pipeline Products By Equipment Type 78
16.3.2 Abbott Laboratories Pipeline Products by Development Stage 78
16.3.3 Abbott Laboratories Pipeline Products by Therapy Area 79
16.3.4 Abbott Laboratories Pipeline Products by Clinical Trials 79
16.3.5 Abbott Laboratories Pipeline Products by News Summary 79
17 Eli Lilly and Company Company Profile 80
17.1 Company Overview 80
17.2 Value Chain Analysis 80
17.2.1 Manufacturing 80
17.2.1.1 In House Manufacturing 80
17.2.1.2 Outsourcing 81
17.2.2 Product Development 81
17.2.2.1 Regulatory Approvals 81
17.2.2.2 Clinical Trials 81
17.2.2.3 Research and Development 81
17.2.3 Sales and Marketing 82
17.2.3.1 Partnerships and Alliances 82
17.2.3.2 Licensing Agreements 82
17.2.3.3 E-distribution 82
17.3 Eli Lilly and Company Pipeline Products 82
17.3.1 Eli Lilly and Company Pipeline Products by Equipment Type 82
17.3.2 Eli Lilly and Company Pipeline Products by Development Stage 82
17.3.3 Eli Lilly and Company Pipeline Products by Therapy Area 83
18 AiMedics Pty Ltd Company Profile 84
18.1 Company Overview 84
18.2 AiMedics Pty Ltd Pipeline Products 84
18.2.1 AiMedics Pty Ltd Pipeline Products by Equipment Type 84
18.2.2 AiMedics Pty Ltd Pipeline Products by Development Stage 84
18.2.3 AiMedics Pty Ltd Pipeline Products by Clinical Trials 84
18.2.4 AiMedics Pty Ltd Pipeline Products by News Summary 85
19 Roche Diagnostics Australia Pty. Ltd. Company Profile 86
19.1 Company Overview 86
20 Appendix 87
20.1 Global Markets Direct Research Methodology 87
20.2 Coverage 88
20.3 Secondary Research 88
20.4 Primary Research 89
20.5 Models 89
20.6 Forecasts 90
20.7 Expert Panels 90
20.8 Currency Conversion 91
20.9 Contact Us 92
20.10 Disclaimer 92

Executive Summary

1.2 List of Figures
Figure 1: Total Healthcare Expenditure in Australia, 2000 - 2005 15
Figure 2: Healthcare Financing Framework in Australia, 2007 16
Figure 3: Healthcare System in Australia, 2007 21
Figure 4: Classification of Medical Devices in Australia, 2007 25
Figure 5: Classification of Noninvasive Devices in Australia, 2007 26
Figure 6: Classification of Invasive Devices in Australia, 2007 27
Figure 7: Classification of Invasive Devices in Australia, 2007 28
Figure 8: Classification of Active Devices in Australia, 2007 29
Figure 9: Classification of Special Medical Devices in Australia, 2007 30
Figure 10: Conformity Assessment Procedure for Medical Devices in Australia, 2007 31
Figure 11: Australia, Medical Equipment Market Comparison, 2007 43
Figure 12: Diabetes Care Devices Cross Country Comparison (2000-2012) 45
Figure 13: Diabetes Care Devices, Australia, Overall Revenues ($ mn), 2000-2012 46
Figure 14: Diabetes Care Devices Market, Australia, Portfolio Analysis 47
Figure 15: Diabetes Care Devices, Australia, Overall Revenues ($ mn), Historic, 2000-2007 48
Figure 16: Diabetes Care Devices, Australia, Overall Revenues ($ mn), Forecast, 2007-2012 49
Figure 17: Diabetes Care Devices, Australia, Category Volume (Units), 2000-2012 50
Figure 18: Diabetes Care Devices, Australia, Category Volume (Units), Historic, 2000-2007 51
Figure 19: Diabetes Care Devices, Australia, Category Volume (Units), Forecast, 2007-2012 52
Figure 20: Diabetes Care Devices, Australia, Company Share (%), 2007 53
Figure 21: Glucose Monitoring, Australia, Revenue ($ mn) by Segment, Historic, 2000-2007 54
Figure 22: Glucose Monitoring, Australia, Revenue ($ mn) by Segment, Forecast, 2007-2012 55
Figure 23: Glucose Monitoring, Australia, Overall Volume (Units), Historic, 2000-2007 56
Figure 24: Glucose Monitoring, Australia, Overall Volume (Units), Forecast, 2007-2012 57
Figure 25: Glucose Monitoring, Australia, Company Share (%), 2007 59
Figure 26: Insulin Delivery, Australia, Revenue ($ mn) by Segment, Historic, 2000-2007 60
Figure 27: Insulin Delivery, Australia, Revenue ($ mn) by Segment, Forecast, 2007-2012 61
Figure 28: Insulin Delivery, Australia, Company Share (%), 2007 64
Figure 29: F. Hoffmann-La Roche Ltd Value Chain Analysis 65
Figure 30: Bayer HealthCare AG Value Chain Analysis 68
Figure 31: Abbott Laboratories Value Chain Analysis 76
Figure 32: Eli Lilly and Company Value Chain Analysis 80
Figure 33: Global Markets Direct Methodology 87

F. Hoffmann-La Roche Ltd.
Bayer HealthCare AG
Novo Nordisk A/S
LifeScan, Inc.
Abbott Laboratories
Eli Lilly and Company
AiMedics Pty Ltd
Roche Diagnostics Australia Pty. Ltd.